PRODUCT MONOGRAPH PRIMAXIN® (imipenem and cilastatin
... same as given for adults above. Renal status of elderly patients may not be accurately portrayed by measurement of BUN or creatinine alone. Determination of creatinine clearance is suggested to provide guidance for dosing in such patients (see PRECAUTIONS / Geriatrics). Adults with Impaired Renal Fu ...
... same as given for adults above. Renal status of elderly patients may not be accurately portrayed by measurement of BUN or creatinine alone. Determination of creatinine clearance is suggested to provide guidance for dosing in such patients (see PRECAUTIONS / Geriatrics). Adults with Impaired Renal Fu ...
HYDROMORPHONE HYDROCHLORIDE TABLETS USP 2 mg, 4
... Geriatric – Age has no effect on the pharmacokinetics of hydromorphone. Gender – Gender has little effect on the pharmacokinetics of hydromorphone. Females appear to have higher Cmax (25%) than males with comparable AUC0-24 values. The difference observed in Cmax may not be clinically relevant. Preg ...
... Geriatric – Age has no effect on the pharmacokinetics of hydromorphone. Gender – Gender has little effect on the pharmacokinetics of hydromorphone. Females appear to have higher Cmax (25%) than males with comparable AUC0-24 values. The difference observed in Cmax may not be clinically relevant. Preg ...
Decreased Serum Concentrations of Tamoxifen
... converts androgens to estrogens in peripheral fat tissue (3). This conversion is the main estrogen source in postmenopausal women. In addition, aminoglutethimide may reduce the con centration of plasma estrogens by enhancement of estrogen metabolism (10, 11). Aminoglutethimide causes response rates ...
... converts androgens to estrogens in peripheral fat tissue (3). This conversion is the main estrogen source in postmenopausal women. In addition, aminoglutethimide may reduce the con centration of plasma estrogens by enhancement of estrogen metabolism (10, 11). Aminoglutethimide causes response rates ...
Codeine Therapy in the Context of Cytochrome P450 2D6
... Hydrocodone is biotransformed by CYP2D6 into hydromorphone, which has a 10- to 33-fold greater affinity for μ-opioid receptors as compared with the parent drug. Relative to extensive metabolizers, poor metabolizers have been shown to have lower peak concentrations of hydromorphone after a dose of hy ...
... Hydrocodone is biotransformed by CYP2D6 into hydromorphone, which has a 10- to 33-fold greater affinity for μ-opioid receptors as compared with the parent drug. Relative to extensive metabolizers, poor metabolizers have been shown to have lower peak concentrations of hydromorphone after a dose of hy ...
Zoloft Cns Drug (Sertraline) Sertraline Cns Depressant (Zoloft) Is
... Dosing elderly causing tremors gambe-leonardo.eu zoloft cns drug taking lunesta and. Is or celexa better for anxiety tooth pain does zoloft show on drug test 5 months lawsuit for. Side effects tinnitus can I take with naproxen zoloft order and use online paypal buspar anxiety how long will side effe ...
... Dosing elderly causing tremors gambe-leonardo.eu zoloft cns drug taking lunesta and. Is or celexa better for anxiety tooth pain does zoloft show on drug test 5 months lawsuit for. Side effects tinnitus can I take with naproxen zoloft order and use online paypal buspar anxiety how long will side effe ...
Reyataz - Products - Bristol
... PPIs and H2RAs in adults also apply to pediatric patients. See Drug Interactions (7) for instructions concerning coadministration of acid reducing medications (eg, H2RA or PPIs), and other antiretroviral drugs (eg, efavirenz, tenofovir, and didanosine). b For pediatric patients at least 25 kg who ca ...
... PPIs and H2RAs in adults also apply to pediatric patients. See Drug Interactions (7) for instructions concerning coadministration of acid reducing medications (eg, H2RA or PPIs), and other antiretroviral drugs (eg, efavirenz, tenofovir, and didanosine). b For pediatric patients at least 25 kg who ca ...
vigamox - Vision Institute of Canada
... total of 13 doses. The mean steady-state Cmax and AUC were 2.7 ng/mL and 41.9 ngAhr/mL, respectively. These systemic exposure values were at least 1,600 and 1,000 times lower than the mean Cmax and AUC reported after therapeutic 400 mg oral doses of moxifloxacin. The plasma half-life of moxifloxacin ...
... total of 13 doses. The mean steady-state Cmax and AUC were 2.7 ng/mL and 41.9 ngAhr/mL, respectively. These systemic exposure values were at least 1,600 and 1,000 times lower than the mean Cmax and AUC reported after therapeutic 400 mg oral doses of moxifloxacin. The plasma half-life of moxifloxacin ...
Product Information - Therapeutic Goods Administration
... integrase strand transfer inhibitor raltegravir depending on the type and number of mutations. Viruses expressing the T66I/A mutations maintain susceptibility to raltegravir, while most other patterns showed reduced susceptibility to raltegravir. Pharmacodynamics Effects on Electrocardiogram The ele ...
... integrase strand transfer inhibitor raltegravir depending on the type and number of mutations. Viruses expressing the T66I/A mutations maintain susceptibility to raltegravir, while most other patterns showed reduced susceptibility to raltegravir. Pharmacodynamics Effects on Electrocardiogram The ele ...
US Product Labeling @std Template for PLR
... Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment. ...
... Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment. ...
Colchicine for pericarditis: hype or hope? REVIEW Massimo Imazio , Antonio Brucato
... was found. In the recently published open-label clinical trial (COPE), colchicine, as adjunct to conventional treatment, significantly decreased the subsequent recurrence rate (actuarial rates at 18 months were, respectively, 10.7 vs. 32.3%, P ¼ 0.004; NNT ¼ 5.0) and symptoms persistence at 72 h (re ...
... was found. In the recently published open-label clinical trial (COPE), colchicine, as adjunct to conventional treatment, significantly decreased the subsequent recurrence rate (actuarial rates at 18 months were, respectively, 10.7 vs. 32.3%, P ¼ 0.004; NNT ¼ 5.0) and symptoms persistence at 72 h (re ...
SUMMARY OF PRODUCT CHARACTERISTIC
... Before initiating treatment, samples should be taken for microbiological analysis, and the suitability of the therapy should subsequently be confirmed (see section 4.2 and section 5.1). In some patients with severe cryptococcal meningitis the mycological response during fluconazole treatment may be ...
... Before initiating treatment, samples should be taken for microbiological analysis, and the suitability of the therapy should subsequently be confirmed (see section 4.2 and section 5.1). In some patients with severe cryptococcal meningitis the mycological response during fluconazole treatment may be ...
PRODUCT MONOGRAPH
... Adverse events have been recorded during controlled clinical investigations in over 13,000 patients exposed to pantoprazole sodium as the single therapeutic agent for treatment of conditions requiring acid suppression. The following adverse reactions considered possibly, probably, or definitely rela ...
... Adverse events have been recorded during controlled clinical investigations in over 13,000 patients exposed to pantoprazole sodium as the single therapeutic agent for treatment of conditions requiring acid suppression. The following adverse reactions considered possibly, probably, or definitely rela ...
PRILOSEC (omeprazole) (omeprazole magnesium) DELAYED-RELEASE CAPSULES
... antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with PRILOSEC, refer to WARNINGS and PRECAUTIONS sections of those package inserts. 5.4 Interaction with Clopidogrel Avoid concomitant use of PRILOSEC with cl ...
... antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with PRILOSEC, refer to WARNINGS and PRECAUTIONS sections of those package inserts. 5.4 Interaction with Clopidogrel Avoid concomitant use of PRILOSEC with cl ...
Product Information for fluticasone propionate and azelastine
... Study MP4001 compared DYLASTINE 125/50 with commercial azelastine nasal spray (Astelin® Nasal Spray) and commercial Fluticasone propionate Nasal Spray from Roxane Laboratories Inc available in the US at that time. Studies MP4002, MP4004, and MP4006 compared DYLASTINE 125/50 with the single compounds ...
... Study MP4001 compared DYLASTINE 125/50 with commercial azelastine nasal spray (Astelin® Nasal Spray) and commercial Fluticasone propionate Nasal Spray from Roxane Laboratories Inc available in the US at that time. Studies MP4002, MP4004, and MP4006 compared DYLASTINE 125/50 with the single compounds ...
Azithromycin for Injection, USP
... In vitro and in vivo studies to assess the metabolism of azithromycin have not been performed. Elimination Plasma concentrations of azithromycin following single 500-mg oral and I.V. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination h ...
... In vitro and in vivo studies to assess the metabolism of azithromycin have not been performed. Elimination Plasma concentrations of azithromycin following single 500-mg oral and I.V. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination h ...
HIGHLIGHTS OF PRESCRIBING INFORMATION
... Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clarithromycin and amoxicillin, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administra ...
... Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clarithromycin and amoxicillin, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administra ...
Patient`s Instructions for Use Albuterol Sulfate Inhalation Solution
... seen in yeast strain S. cerevisiae S9 nor any mitotic gene conversion in yeast strain S. cerevisiae JD1 with or without metabolic activation. Fluctuation assays in S. typhimurium TA98 and E. coli WP2, both with metabolic activation, were negative. Albuterol sulfate was not clastogenic in a human per ...
... seen in yeast strain S. cerevisiae S9 nor any mitotic gene conversion in yeast strain S. cerevisiae JD1 with or without metabolic activation. Fluctuation assays in S. typhimurium TA98 and E. coli WP2, both with metabolic activation, were negative. Albuterol sulfate was not clastogenic in a human per ...
LIPIDIL MICRO PM
... decreasing the low density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fenofibrate increases the high density lipoprotein (HDL) cholesterol fraction. Fenofibrate appears to have a greater depressant effect on ...
... decreasing the low density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fenofibrate increases the high density lipoprotein (HDL) cholesterol fraction. Fenofibrate appears to have a greater depressant effect on ...
PANTOPRAZOLE SODIUM DELAYED-RELEASE
... midazolam, and clarithromycin (CYP3A4 substrates), metoprolol (a CYP2D6 substrate), diclofenac, naproxen and piroxicam (CYP2C9 substrates) and theophylline (a CYP1A2 substrate) in healthy subjects, the pharmacokinetics of pantoprazole were not significantly altered. It is, therefore, expected that o ...
... midazolam, and clarithromycin (CYP3A4 substrates), metoprolol (a CYP2D6 substrate), diclofenac, naproxen and piroxicam (CYP2C9 substrates) and theophylline (a CYP1A2 substrate) in healthy subjects, the pharmacokinetics of pantoprazole were not significantly altered. It is, therefore, expected that o ...
Current topical and systemic approaches to treatment of rosacea
... reduced by nearly 50% by week 12.22 For a long time, a twice-daily application of 0.75% gel formulation was considered to be the optimal dosage until the effectiveness of a once-daily dosage of 0.75% and 1% metronidazole formulation could be shown in a 12week, randomized study.23 In 2006, it was mor ...
... reduced by nearly 50% by week 12.22 For a long time, a twice-daily application of 0.75% gel formulation was considered to be the optimal dosage until the effectiveness of a once-daily dosage of 0.75% and 1% metronidazole formulation could be shown in a 12week, randomized study.23 In 2006, it was mor ...
Diltiazem Hydrochloride Extended-Release Capsules, USP
... normotensive individuals and, in exercise tolerance studies in patients with ischemic heart disease, reduces the heart rate-blood pressure product for any given work load. Studies to date, primarily in patients with good ventricular function, have not revealed evidence of a negative inotropic effect ...
... normotensive individuals and, in exercise tolerance studies in patients with ischemic heart disease, reduces the heart rate-blood pressure product for any given work load. Studies to date, primarily in patients with good ventricular function, have not revealed evidence of a negative inotropic effect ...
oxycodone controlled release tablets
... and patients should be titrated to pain relief unless unmanageable adverse drug reactions prevent this. If higher doses are necessary, increases should be made, where possible, in 25% - 50% increments. The need for escape medication more than twice a day indicates that the dosage of Oxycodone Contro ...
... and patients should be titrated to pain relief unless unmanageable adverse drug reactions prevent this. If higher doses are necessary, increases should be made, where possible, in 25% - 50% increments. The need for escape medication more than twice a day indicates that the dosage of Oxycodone Contro ...
SPC Ciprofloxacin 200mg/100mL solution for infusion
... Clinical trials have included children and adolescents aged 5-17 years. More limited experience is available in treating children between 1 and 5 years of age. Complicated urinary tract infections and pyelonephritis Ciprofloxacin treatment of urinary tract infections should be considered when other ...
... Clinical trials have included children and adolescents aged 5-17 years. More limited experience is available in treating children between 1 and 5 years of age. Complicated urinary tract infections and pyelonephritis Ciprofloxacin treatment of urinary tract infections should be considered when other ...
lipidil supra pm
... products due to the risk of hypersensitivity reactions. The drug should not be used during pregnancy and breast-feeding. Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen. Should not be co-administered with HMG-CoA reductase inhibitors (statins) in patients with ...
... products due to the risk of hypersensitivity reactions. The drug should not be used during pregnancy and breast-feeding. Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen. Should not be co-administered with HMG-CoA reductase inhibitors (statins) in patients with ...
PRODUCT MONOGRAPH ACCUTANE™ ROCHE isotretinoin
... Pregnancy Tests: Female patients of childbearing potential must not be given ACCUTANE until pregnancy is excluded. The patient must have two negative pregnancy tests before starting ACCUTANE therapy with the first pregnancy test conducted at initial assessment when the patient is qualified for ACCUT ...
... Pregnancy Tests: Female patients of childbearing potential must not be given ACCUTANE until pregnancy is excluded. The patient must have two negative pregnancy tests before starting ACCUTANE therapy with the first pregnancy test conducted at initial assessment when the patient is qualified for ACCUT ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.